BSG BioNewsLetter 08#2002 - BioSeeker Group's analysis and products eNewsletter
URL: http://www.bioseeker.com http://www.bsg-online.biz
-- CONTENTS --
1) Raiders of the Lost Ark - Immunomodulators the Big Winners?
2) New Report: 'Future HCV Drug Discovery Technologies'
3) BioSeeker launches BioNewsletter Pro
4) BioSeeker in Strategic Use of SkyMinder
5) Recently Published Reports
6) Conference Opportunity - BioBusiness 2003
7) Coming reports: HCV Therapy / Winning the Osteoporosis Therapy Race
8) Subscription
9) BioSeeker Online Store
====================================================================
1) RAIDERS OF THE LOST ARK - IMMUNOMODULATORS THE BIG WINNERS?
There is still a strong interest in developing new immunomodulating therapies for HCV despite the promise of the pegylated interferons. There is also an increasing enthusiasm for targeting HCV molecular products such as protease inhibitors. The understanding of hepatitis C at a molecular level has also opened the door for more targeted development of a prophylactic or therapeutic HCV vaccine.
Read the full version of this free, analytical BioNewsletter article at http://www.bioseeker.com/docs/topics/topic_hcv2.asp
====================================================================
2) FUTURE HCV DRUG DISCOVERY TECHNOLOGIES
- A new report from BioSeeker Group
The main hindrance to drug development for hepatitis C has been the lack of a small animal model or productive tissue culture system for assessing drug action. This problem has been addressed both by academic groups and private companies, which has resulted in a drastic improvement of the possibilities for in vivo research. The main obstacle has clearly been difficulty of achieving viral replication in the laboratory both in cell culture and animal models. This is about to change. Several groups are now generating models with a possible ability to revolutionize HCV drug discovery.
In this highlight report, we focus on describing and assessing the ongoing struggle for improved and novel HCV drug discovery technologies. Technological breakthroughs have been made and BioSeeker Group has identified improvements for new drug discovery platforms that have the potential to substantially improve HTS.
For more information about this report, please visit http://www.bioseeker.com/index.asp?report=hcv2
====================================================================
3) BIOSEEKER LAUNCHES BIONEWSLETTER PRO
As a subscriber of the BioNewsletter Pro you will receive 26 issues per year of in-depth, analytical articles on hot topics in the biotech and pharma industries. BioNewsLetter Pro provides you with in-depth coverage, candid information and analysis of different fields within biotechnology and pharmaceutical industry. We identify different areas of special interest and provide you with highly updated information including interviews with key people in the field. Further, our BioNewsLetter Pro issues present in-depth analysis and evaluation of different technology platforms, future projections, where BioSeeker Group subjectively discusses and assesses possible outcomes for technologies or companies.
Further, when signing up as a subscriber you will receive one of the following BioSeeker reports, entirely free of charge:
- Pan-European Investors in the Biotechnology Industry
- Swedish Investors in Biotechnology
- Swedish Biotechnology Industry
- In Depth Financial Report on the Swedish Biopharma Branch 2002
- R&D in Swedish Biopharma Companies 2002
You will also be available to take advantage of certain discount offers. For more information, please visit www.bioseeker.com.
====================================================================
4) BIOSEEKER GROUP IN STRATEGIC USE OF SKYMINDER
BioSeeker Group's intelligence is now further enhanced by the strategic use of SkyMinder, the ideal tool for business information from the highest quality information sources all over the world, all accessible on-line and in real time.
To give the BSG BioNewsletter readers the very best, we have asked SkyMinder to highlight their capabilities in providing world wide company information on the biotechnology and pharmaceutical industry through our website www.bioseeker.com.
====================================================================
5) RECENTLY PUBLISHED BIOSEEKER REPORTS
- Ion Channels as Therapeutic Targets for Multiple Diseases (released Nov, 2002)
http://www.bioseeker.com/index.asp?report=ionchanneltargets
- New Targets and Drug Discovery Platforms in Antifungal R&D (released Nov, 2002)
http://www.bioseeker.com/index.asp?report=antifungal2
- Fierce Competition for a Shrinking HCV Market? (released Oct, 2002)
http://www.bioseeker.com/index.asp?report=hcv1
- The Next Generation Antifungals: Triazoles vs. Peptides
http://www.bioseeker.com/index.asp?report=antifungal (released Oct, 2002)
- Swedish Biopharma Industry - The Next Wave (released Sept, 2002)
http://www.swedishpharma.info
- Ion Channel Assays in the Drug Discovery Process (released June, 2002)
http://www.ion-channels-in-drug-discovery.info
- Commercializing on Tumor Antigens: Analytical Perspectives (released Feb, 2002)
http://www.commercializing-tumor-antigens.info
====================================================================
6) CONFERENCE OPPORTUNITY - BioBusiness 2003
BioBusiness 2003 is the premier bio-partnering event for biotech and pharma business development and licensing executives. At this senior-levelinternational event you won't have to trawl through your 200 fellow attendees to find fellow business development and licensing professionals as these are the only biotech and pharma representatives coming! So instead of wasting your time looking for them, you can concentrate on discussing strategies with them in interactive roundtable groups or formulating future plans with them in private one-to-one meetings. Plus you can learn from the best! Hear from 16 leading pharmaceuticals and 15 world class biotechs, such as Novartis, F. Hoffman La Roche, Boehringer Ingelheim, Aventis, Genentech, Genzyme and Vertex Pharmaceuticals, who will tell you what they are currently looking for in business partners and how they see alliance and partnering strategies developing in the next five years. Book your place now!
For more information, please visit www.wbresearch.com/biobusiness or contact Colin Chapman (colin2---wbr.co.uk)
====================================================================
7) COMING REPORTS
- Complete Guide to Molecular Approaches for HCV Therapy
Treatment of HCV (Hepatitis C Virus) is a market with unmet medical needs, with relatively young people infected and a high risk for chronic disease. The coming decade will see exciting developments in HCV therapy thanks to breakthroughs in overcoming a major barrier to development: the lack of dedicated models suitable for validating candidate compounds in a low-cost, highthroughput format. BioSeeker Group has identified at least 115 companies with interest in various stages in the field of HCV therapy. Out of these 100, approximately 10 of the 'big pharma' are represented. Our coming report "Complete Guide to Molecular Approaches for HCV Therapy" analyses the field of new HCV therapeutics and assess possible outcomes for drugs and companies in this sector.
Please contact us at bioinfo() bioseeker.com for more information about this report.For further reading about HCV, please visit our free analytical article on this topic (http://www.bioseeker.com/docs/topics/topic_hcv.asp)
- Winning the Osteoporosis Therapy Race
Osteoporosis, deterioration of bone tissue and an increased risk of fractures, is considered by the World Health Organization to be second only to cardiovascular disease as a leading healthcare problem. According to other studies, sales of osteoporosis drugs in these markets totaled $3.4 billion in 2000, and are expected to reach $6.5 billion by 2005. A new class of osteoporosis therapies, designed to build bone mass in contrast to currently available anti-osteoporosis medicines are presently under study. These anabolic therapies consist of parathyroid hormone (FortÎoª and ALX-11) or fluoride to stimulate bone formation, but their safety and efficacy remain to be established. The first of these drugs to reach the market will probably be FortÎoª, known generically as teriparatide (recombinant parathyroid hormone).
Please contact us for more information about this report (bioinfo+*+bioseeker.com). For further reading about osteoporosis, please visit our free analytical article on this topic (http://www.bioseeker.com/docs/topics/topic_osteoporosis.asp)
- Advancements in Colon Cancer Therapeutics
In this report, BioSeeker has indentified a number of emerging strategies for colon cancer therapeutics. The report discusses and assesses early and late stage projects in this area. BioSeeker focuses on the areas regarded as the "hottest leads" at the moment.
For more information about this report, please contact us at bioinfo.:.bioseeker.com
- A Shift in Cancer Immunotherapy Strategies?
For more information about this report, please contact us at bioinfo _ bioseeker.com
====================================================================
8) SUBSCRIPTION
To continue to stay tuned with coming editions of BioSeeker Groups free BioNewsLetter, please send an email to subscribe|a|bioseeker.com
============================================================================
9) BIOSEEKER ONLINE STORE
BioSeeker has now made it easy to order any of our products online, directly from our website. Visit www.bsg-online.biz to place an online order.
============================================================================
ADVERTISING
Do you have a message that you would like the biotech community to know? BioSeeker Group's Newsletter targets managers, scientists, venture capitalists, consultants and many more world wide. Contact us at sales-,-bioseeker.com for further information on how to advertise in BSG BioNewsletter.
COURTESY
If you would like to comment on our newsletter please send us an email to feedback]|[bioseeker.com
If you would like to be removed from our newsletter list, please reply to unsubscribe]_[bioseeker.com
Received on 2002-12-02 - 12:33 GMT
This archive was generated by hypermail 2.2.0 : 2005-11-24 - 10:21 GMT